🟢 Anixa Biosciences is trading 6.2% up in pre-market; catalyst remains unclear

Anixa Biosciences is trading 6.19% up at $3.09 in pre-market on October 9, 2026, with no clear catalyst identified.

• The October 8 close was $2.91; supplied price context shows a rebound after mostly lower sessions, including a 6.50% rise on October 2.
• No October 9 company announcement was identified. The latest company-specific news was an October 5 update reporting the first stable-disease response at 90 days in its ovarian cancer CAR-T trial; it predates the move, and a direct link is unclear.
• Broader indices are higher, but the Nasdaq’s 0.80% gain alone does not establish the cause.